FindTrial
Sign In

RESITUNE 100 mg

DRUG3 trials

Sponsors

Centre Hospitalier Universitaire De Saint Etienne, Institut Gustave Roussy, Centre Hospitalier Regional Et Universitaire De Brest

Conditions

Castration-resistant prostate cancerPhiladelphia-negative myeloproliferative neoplasms are frequent and chronic myeloid malignancies including Polycythemia Vera (PV)Primary Myelofibrosis (PMF) and Prefibrotic myelofibrosis (PreMF).acute venous thromboembolism eventessential thrombocythemia (ET)

Phase 2

Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms
Not yet recruitingCTIS2024-515362-13-00
Centre Hospitalier Regional Et Universitaire De Brestessential thrombocythemia (ET), Philadelphia-negative myeloproliferative neoplasms are frequent and chronic myeloid malignancies including Polycythemia Vera (PV), Primary Myelofibrosis (PMF) and Prefibrotic myelofibrosis (PreMF).
Target: 1008Updated: 2025-07-11

Phase 3

Best Antithrombotic Therapy in patients with acute Venous ThromboEmbolism while taking antiplatelets: the BAT-VTE
RecruitingCTIS2022-500974-33-00
Centre Hospitalier Universitaire De Saint Etienneacute venous thromboembolism event
Start: 2023-08-12Target: 1400Updated: 2025-04-25
A Phase III trial of acetylsalicylic acid and atorvastatin in patients with castrate-resistant prostate cancer (PEACE 4)
RecruitingCTIS2023-508072-11-00
Institut Gustave RoussyCastration-resistant prostate cancer
Start: 2019-06-26Target: 1210Updated: 2025-12-10